Telegram RegisterThe public register of Telegram
Telegram profile photo for 허혜민의 제약/바이오 소식통

Channel

허혜민의 제약/바이오 소식통

@huhpharm

On this record: Topic · Growth · Engagement · What this channel posts · Posts · Citations · Telegram's recommendations · Cite this entry

24,282subscribers

+363 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001381339396
TypeChannel
Username@huhpharm
Description제약/바이오 뉴스, 업데이트, 발간자료 공유
Created12 July 2020 — measured — cross-checked against a third-party dataset (ext.tg_channel)
First recorded6 August 2026
Last confirmed live18 September 2026
Measurements held33
Confirmed unchanged1 time, most recently 18 September 2026
On Telegramt.me/huhpharm

Topic

Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 10 September 2026 and assigned it the closest of 31 fixed categories, at 64% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.

Growth

23,89024,28224,0866 August 2026 — 23,919 subscribers6 August 2026 — 23,918 subscribers8 August 2026 — 23,915 subscribers9 August 2026 — 23,909 subscribers11 August 2026 — 23,900 subscribers12 August 2026 — 23,892 subscribers13 August 2026 — 23,890 subscribers14 August 2026 — 23,911 subscribers16 August 2026 — 23,912 subscribers17 August 2026 — 23,910 subscribers18 August 2026 — 23,898 subscribers19 August 2026 — 23,969 subscribers20 August 2026 — 23,978 subscribers21 August 2026 — 24,004 subscribers22 August 2026 — 24,069 subscribers24 August 2026 — 24,097 subscribers25 August 2026 — 24,134 subscribers26 August 2026 — 24,152 subscribers27 August 2026 — 24,157 subscribers28 August 2026 — 24,154 subscribers29 August 2026 — 24,151 subscribers30 August 2026 — 24,152 subscribers31 August 2026 — 24,158 subscribers1 September 2026 — 24,165 subscribers2 September 2026 — 24,152 subscribers3 September 2026 — 24,174 subscribers5 September 2026 — 24,167 subscribers8 September 2026 — 24,161 subscribers11 September 2026 — 24,169 subscribers13 September 2026 — 24,218 subscribers14 September 2026 — 24,223 subscribers16 September 2026 — 24,269 subscribers18 September 2026 — 24,282 subscribers6 August 202618 September 2026
33 measurements spanning 44 days, net +363. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 23,831–24,341 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 33
Measured (UTC)SubscribersChange
18 Sept 2026, 17:1924,282+13
16 Sept 2026, 10:3924,269+46
14 Sept 2026, 18:2024,223+5
13 Sept 2026, 06:0024,218+49
11 Sept 2026, 07:2124,169+8
8 Sept 2026, 14:5724,161-6
5 Sept 2026, 09:4024,167-7
3 Sept 2026, 15:2024,174+22
2 Sept 2026, 05:0524,152-13
1 Sept 2026, 05:4324,165+7
31 Aug 2026, 09:0224,158+6
30 Aug 2026, 11:4524,152+1
29 Aug 2026, 14:5424,151-3
28 Aug 2026, 12:3824,154-3
27 Aug 2026, 15:3324,157+5
26 Aug 2026, 16:2324,152+18
25 Aug 2026, 19:5124,134+37
24 Aug 2026, 17:3624,097+28
22 Aug 2026, 22:5324,069+65
21 Aug 2026, 15:1724,004first reading

Engagement

151 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 59 pages of Telegram’s post history, 20 posts per page.

ERR · 30 days
17.0%
avg views ÷ 24,282 subscribers
Avg views / post
4,140
43 posts measured
Reaction rate
—
this channel exposes no reaction counts
Posts in window
43
of 151 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 26 September 2026
Posts held151 (4 August 2026 – 26 September 2026)
Views total177,810
Reactions total—
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken26 Sept 2026, 23:52 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

What this channel posts

Photos
≈1,910
Videos
≈2
Links
≈3,540

Lifetime counters from Telegram’s own channel header, read 26 September 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked ≈ was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.

Recent posts

26 Sept 2026, 10:30 UTC≈2,710 viewsread 26 September 2026

"허가·중단·재신청…" 추석 연휴 'K바이오 운명' 갈랐다 HLB '리픽투' 美 FDA 품목허가 셀트리온 짐펜트라 美 3상 승인 한올 루푸스 적응증 개발 중단 삼성제약 GV1001 3상 IND 자진취하 온코닉 中 3상 진입·마일스톤 확보 https://www.fnnews.com/news/202609251605362802

Signed 혜민 허

25 Sept 2026, 10:00 UTC≈2,640 viewsread 26 September 2026
Forwarded from @YeouidoStory2

美 의약품 관세 조치서 韓 0% 면세 확정…K-바이오 ‘100% 관세 폭탄’ 피했다 https://n.news.naver.com/mnews/article/016/0002701685?sid=101

Signed 혜민 허

25 Sept 2026, 03:39 UTC≈6,800 viewsread 26 September 2026

[키움 허혜민] Novo Nordisk, 월·분기 1회 비만 치료제 개발 위해 Nanexa와 최대 €1.165bn 계약 Novo Nordisk, 스웨덴 약물전달 플랫폼 기업 Nanexa와 최대 €1.165bn 규모 글로벌 독점 라이선스 및 협력 계약 체결 Novo는 Nanexa의 PharmaShell 약물전달 플랫폼을 비만, 2형 당뇨 및 기타 심혈관·대사질환의 특정 펩타이드 치료제에 적용할 수 있는 글로벌 독점 권리 확보. 최대 5개 개발 프로그램 포함 특히 투여 편의성 개선을 위해 서로 다른 지속형 제형을 개발하며 월 1회(monthly) 및 분기 1회(quarterly) 투여를 목표로 개발 Nanexa는 upfront와 개발·허가 마일스톤을 합쳐 최대 €615mn, 판매 마일스톤까지 포함하면 총 €1.165bn 수령 가능. 향후 …

Signed 혜민 허

25 Sept 2026, 00:08 UTC≈3,100 viewsread 26 September 2026

[키움 허혜민] 미국 상원의원이 대통령과 친분이 있는 바이오텍 업계 리더를 백악관에 앉히고 싶어하는 이유 NSCEB는 지난해 미국 바이오 산업의 미래를 위한 49개 정책 권고안 발표. 바이오를 국가 차원에서 우선순위화하고 민간 부문 활성화, 바이오의 군사적 활용 극대화, 동맹국 역량 강화, 인력 확대 등에 초점 미 국가안보신흥바이오기술위원회(NSCEB) 위원장 Todd Young 상원의원, 미·중 바이오파마 파트너십을 하루아침에 차단하는 것은 현실적이지 않지만, 장기적으로 중국에 대한 전략적 의존도를 낮춰야 한다고 강조. Young 의원은 최우선 과제로 백악관 내 연방 바이오 리더 신설을 제시. 각 정부기관을 아우르는 바이오 전략을 수립하고 기관장들과 전략적 우선순위를 조율하는 역할 Young 의원은 미국 내 혁신기업과 제조업체 지원,…

Signed 혜민 허

24 Sept 2026, 23:51 UTC≈2,620 viewsread 26 September 2026

[키움 허혜민] Boehringer Ingelheim, 중국 Shanghai 바이오 CDMO 사업 매각 Boehringer Ingelheim, 중국 바이오의약품 CDMO 자회사 지분 100%를 Shanghai Raas Blood Products에 최대 RMB 20mn(약 $3mn)에 매각 2014년 Shanghai에 설립된 바이오의약품 CDMO로 임상부터 상업 생산, CMC 허가 지원, 분석법 개발·검증 등의 서비스 제공. 상업생산 가능한 6,000L 규모 생산시설 보유 2025년 순손실 RMB 259mn(약 $38.5mn), 2026년 1분기에도 약 $2.5mn 적자 기록 현지 보도에 따르면 WuXi Biologics 등 중국 로컬 CDMO 업체와의 경쟁에 어려움을 겪어온 것으로 알려짐. Boehringer는 중국 사업 전략 조정에 …

Signed 혜민 허

24 Sept 2026, 23:38 UTC≈2,760 viewsread 26 September 2026

[키움 허혜민] Novo Nordisk CEO, 미국 직접 상장 가능 Novo CEO Mike Doustdar, 현재 미국 투자자들이 거래하는 ADR을 직접 상장 주식으로 전환하는 방안에 장점이 있을 수 있다며 미국 직접 상장 가능성에 열린 입장이라고 FT 인터뷰에서 언급 다만 현재 직접 상장을 검토하거나 적극적으로 논의하고 있는 것은 아니라고 설명. Novo는 미국 매출이 전체의 절반 이상이며, GLP-1 매출도 미국이 과반 차지 AstraZeneca도 올해 미국 투자자 유치를 위해 유사한 방식의 미국 직접 상장을 추진. 최근 Novo는 Lilly의 Mounjaro·Zepbound와의 경쟁 심화로 특히 미국 대사질환 시장 점유율이 압박받고 있으며, Ascendis와의 TransCon 협력 종료 및 ziltivekimab 3상 실패 등…

Signed 혜민 허

24 Sept 2026, 09:14 UTC≈2,400 viewsread 26 September 2026
Forwarded from @thebio111

[진양곤 의장 소회] "회사에게도 주주 여러분께도 참으로 모진 시간들이었습니다. 더 나은 성과로 보답하겠습니다." 진양곤 HLB그룹 이사회 의장이 담관암 신약 '리픽투(성분 리라푸그라티닙)'의 FDA 승인 소식을 전하며 꺼낸 말입니다. 진 의장은 24일 유튜브 영상에서 신약 개발 과정을 '20년간의 여정'으로 돌아보며 임직원과 주주에게 감사를 표했습니다. 그룹의 첫 신약 개발을 완성시킨 진 의장은 그동안의 소회와 함께 승인 이후의 사업 계획을 밝혔습니다. "실패에 굴하지 않는 것이 어느새 우리 HLB의 상징적인 조직문화가 됐다" "글로벌 항암 신약을 보유한 회사가 되었다는 성과가 더해지면서 해낼 수 있다는 자신감이 회사 내에 퍼지게 된 점은 이번 신약 승인이 가져온 가장 큰 선물일 것" "남이 개발해서 성과를 내주기를 기다려야만 하는…

Signed 혜민 허

24 Sept 2026, 09:13 UTC≈3,130 viewsread 26 September 2026
Forwarded from @thebio111

[종합] 한올바이오파마가 기술수출한 ‘아이메로프루바트(IMVT-1402)’가 피부 홍반성 루푸스 임상에서 1차 평가지표 달성에 실패하며 해당 적응증 개발을 중단합니다. 다만 면역글로불린G(IgG) 감소 효과와 안전성을 재확인한 만큼 그레이브스병과 난치성 류머티즘 관절염, 중증 근무력증 등 핵심 적응증의 임상 개발과 상용화는 예정대로 추진합니다. 한올바이오파마의 미국 파트너사인 이뮤노반트(Immunovant)는 23일(현지시간) 차세대 FcRn 억제제 후보물질인 ‘IMVT-1402’가 피부 홍반성 루푸스 환자를 대상으로 한 개념증명(PoC) 임상2상에서 1차 평가변수를 충족하지 못했으며, 해당 적응증에 대한 개발을 중단한다고 밝혔습니다. IMVT-1402는 한올바이오파마가 자체 개발한 FcRn 억제제 기술을 바탕으로 하며, 지난 2017년…

Signed 혜민 허

23 Sept 2026, 23:37 UTC≈3,530 viewsread 26 September 2026

https://marketin.edaily.co.kr/News/ReadE?newsId=01321846645583400 당사 목표가 산정에 피부 홍반성 루푸스(CLE) 적응증은 목표주가에 미포함

Signed 혜민 허

23 Sept 2026, 22:58 UTC≈3,500 viewsread 26 September 2026

m.yakup.com/news/index.html?mode=view&pmode=&cat=12&cat2=&nid=332964&num_start=

Signed 혜민 허

22 Sept 2026, 22:46 UTC≈4,270 viewsread 26 September 2026

26/09/23 (수) 키움 제약바이오 데일리 💊 [제약/바이오 Analyst 허혜민, RA 김종현] 키움 제약/바이오/의료기기 소식통: t.me/huhpharm <‍📈 주요 지수 등락> * 코스피 +0.15% vs 코스피 제약 -1% * 코스닥 -0.23% vs 코스닥 제약 -2.25% * S&P500 +0% vs XBI +2.3% * 나스닥 +0.45% vs NBI +1.67% <‍🇰🇷 국내 주요 뉴스 🔥> *괄호 안은 전일 수익률 ★ FDA, '토베시미그' 허가신청 전 생존이익 입증 임상 권고…美컴퍼스 "새 임상 불필요" (-5.19%) - 임상2/3상서 ORR·PFS 개선…OS는 통계적으로 유의한 차이 미확인 - 컴퍼스, 기존 데이터·미충족 의료 수요 근거로 불필요 판단…FDA와 추가 협의 계획 -> https://tinyur…

Signed Jonghyun Kim

22 Sept 2026, 13:43 UTC≈4,980 viewsread 26 September 2026

[키움 허혜민] Compass, 담도암 Tovecimig 허가 전 생존기간 입증 추가 임상 FDA 권고 Compass Therapeutics, FDA가 이전 치료 경험이 있는 진행성 담도암(BTC) 대상 tovecimig BLA 제출에 앞서 생존기간(OS) 이점을 입증하는 추가 임상을 진행할 것을 권고. Compass는 당초 올해 말 BLA 제출을 추진 Compass는 2/3상 COMPANION-002 결과와 높은 미충족 수요를 근거로 BLA 제출 전 새로운 임상이 필요하지 않다는 입장. FDA와 추가 논의를 진행하면서 BLA 제출 준비 지속 예정 COMPANION-002에서 tovecimig+paclitaxel은 paclitaxel 단독 대비 1차 지표인 ORR 18.0% vs 5.3%(p=0.0228)로 통계적 유의성 확보 mPFS…

Signed 혜민 허

Showing the 12 most recent of 151 posts we hold for @huhpharm. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Forward network

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 8 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Channels Telegram recommends alongside this one

Telegram’s own answer, not this register’s. When this register asks Telegram’s API what is similar to this channel, this is the list it returns, in the exact order Telegram returns it — never re-sorted by subscribers or by anything else this register measures. The relationship, and the order, are Telegram’s; we record them and date them, and make no claim of our own about which of these channels actually resemble this one.

김찰저의 관심과 생각 저장소
@kimcharger · 24,877
#1
AWAKE - 52주 신고가 모니터링
@awake_realtimeCheck · 22,632
#2
한양증권 제약/바이오 오병용
@bdragon0808 · 13,384
#3
올바른
@allbareun · 12,221
#4
미국 제약-바이오 주식/약장수
@yakjangsu · 11,424
#5
미래에셋 제약/바이오 김승민
@bioksm · 14,926
#6
Stock Trip
@stocktrip · 7,288
#7
글로벌바이오아저씨
@choaz1 · 7,068
#8
쩜상리서치
@upper_limit_price · 8,003
#9
리가켐바이오 IR/PR 공식 채널
@SHIDGL · 10,061
#10
Pluto Research
@hedgehara · 19,075
#11
상장기업 수사대 ☎️
@cyber_rangers · 16,973
#12
선수촌
@athletes_village · 21,621
#13
BUYagra
@psychotherapy101 · 5,959
#14
도PB의 생존투자
@survival_DoPB · 22,243
#15
주식 급등일보🚀급등테마·대장주 탐색기 | Korean Stocks
@FastStockNews · 128,921
#16
제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,812
#17
Yeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,309
#18
영리한 동물원
@stockinvcowcow · 14,059
#19
Buff
@bufkr · 22,185
#20
그로쓰리서치(Growth Research) [독립리서치]
@growthresearch · 40,159
#21
YM리서치
@ym_research · 40,071
#22
[충간지의 글로벌 의료기기/디지털 헬스/로보틱스 연구소]
@globalmedtech · 12,095
#23
가치투자클럽
@corevalue · 67,505
#24
여의도스토리 Ver2.0-习近平是个狗东西
@YeouidoStory2 · 58,411
#25
Macrotrader - 금융치료
@slsyphus · 4,401
#26
Financial Magazine
@hanagae · 4,642
#27
타점 읽어주는 여자(타자)
@tazastock · 40,320
#28
빠르고 정확한 주식정보방
@fastest_info1 · 13,317
#29
유진투자증권 산업분석실 테크/인프라팀
@eugene2team · 6,897
#30
AWAKE - 마켓 브리핑
@awake_schedule · 17,220
#31
잠실개미&10X’s N.E.R.D.S
@jake8lee · 17,256
#32
다올 의료기기/화장품 박종현
@alexppark · 8,503
#33
조기주식회 공부방
@EarlyStock1 · 24,432
#34
탐방봇
@TambangVot · 8,630
#35
실시간 주식 뉴스
@realtime_stock_news · 37,210
#36
BioMoment-Oncology
@biomoment · 3,803
#37
바이오도 간다!
@kkk595959 · 5,713
#38
바이오스펙테이터
@biospectatorT · 5,880
#39
바이오 탐색대
@PathfinderOfBio · 1,107
#40
돼지바
@bbong_tta · 12,692
#41
호그니엘
@hogniel · 15,315
#42
💯똥밭에 굴러도 주식판
@daegurr · 23,375
#43
한투증권 미국/중국전략 정정영
@G2strategy · 16,234
#44
텐렙
@Ten_level · 17,116
#45
야자반 - Y.Z. stock
@yaza_stock · 13,107
#46
양파농장
@Onionfarmer · 15,986
#47
범송공자 X 29PER
@bumsong2 · 13,092
#48
投資, 아레테
@mstaryun · 18,661
#49
기술적 분석으로 보는 주식시장 (by 소라게아빠)
@hermitcrab41_1 · 20,334
#50
에테르의 일본&미국 리서치
@aetherjapanresearch · 34,509
#51
실전매매전략 : 마켓타이밍
@stockgrandmaster · 10,920
#52
CTT Research
@CTTResearch · 6,905
#53
게이머 강석오 [Gamer Seoko Kang]
@seokokang · 6,191
#54
간절한 투자스터디카페
@desperatestudycafe · 18,824
#55
시장 이야기 by 제이슨
@bumgore · 35,352
#56
TRENDSETTER GLOBAL
@TRENDSETTERVERSION2 · 3,934
#57
루팡
@bornlupin · 48,199
#58
Rafiki research
@rafikiresearch · 20,596
#59
AWAKE - 실시간 주식 공시 정리채널
@darthacking · 65,078
#60
디일렉(THEELEC)
@theelec · 10,807
#61
선진짱 주식공부방
@sunstudy1234 · 54,428
#62
투자의 빅 픽처를 위한 퍼즐 한 조각
@investment_puzzle · 14,375
#63
트리플 아이 - Insight Information Indepth
@triple_stock · 12,879
#64
엄브렐라리서치 Jay의 주식투자교실
@Jstockclass · 26,067
#65
하나 중국/신흥국 전략 김경환
@HANAchina · 35,301
#66
이지스스트레티지 리서치
@jeilstock · 26,472
#67
재야의 고수들
@gaoshoukorea · 41,159
#68
한국투자증권/기관영업부/이민근
@mk81_koreainvestment · 16,327
#69
TNBfolio
@TNBfolio · 24,657
#70
유튜브 채부심 Official 채널
@aptvalueprice · 10,716
#71
YIELD & SPREAD
@yieldnspread · 22,018
#72
[메리츠 Tech 김선우, 양승수, 김동관]
@merITz_tech · 24,059
#73
신영증권 박소연
@sypark_strategy · 29,465
#74
반붐온? 방붐온?
@cpshelter · 5,427
#75
뺀지뤼의 SKLab.(스크랩)
@bbanjil · 10,732
#76
레드버드 기업분석
@redbirdstock · 9,963
#77
Thesis
@thesis_true · 2,324
#78
지휘통제실
@Fire_Direction_Center · 5,489
#79
키움 반도체,이차전지 PRIME☀️
@kiwoom_semibat · 12,452
#80
여의도 감성투자
@ygamsung · 6,730
#81
[니커 게임/엔터]
@Nicker0122_1 · 4,135
#82
🗽엄브렐라(Umbrella Research) 리서치+ 네프콘 옆집부자형 since 2020
@umbrellaresearch · 12,831
#83
주식 다람이
@stockDaram2 · 5,122
#84
메리츠 전략 이수정
@KrystalDopamine · 12,288
#85
유진투자증권 코스닥벤처팀
@SmallCap · 23,176
#86
마산창투
@PRROEresearch · 4,630
#87
Nihil's view of data & information
@viewofdata · 12,811
#88
아트합시다.
@Korea_value · 5,488
#89
DAOL 조선/기계/방산 | 최광식
@HI_GS · 17,062
#90
피카츄 아저씨⚡️
@pikachu_aje · 25,217
#91
제이지의 투자이야기
@JgrowthInv · 3,012
#92
[미래 임희석] 인터넷/SW/게임
@mirae_internet · 8,042
#93

Read from Telegram’s recommendation API, most recently 16 September 2026. Telegram holds a list like this for a small and growing share of the register — how this is measured, and why most channel pages show nothing here.

Appears in Telegram’s recommendations for other channels

The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.

제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,812
Telegram ranks this channel #27 of 89 here — alongside 88 others — read 7 September 2026
키움증권 미국주식 톡톡
@kwusa · 36,480
Telegram ranks this channel #53 of 92 here — alongside 91 others — read 2 September 2026
가치투자클럽
@corevalue · 67,505
Telegram ranks this channel #53 of 93 here — alongside 92 others — read 2 September 2026
실시간 주식 뉴스
@realtime_stock_news · 37,210
Telegram ranks this channel #59 of 93 here — alongside 92 others — read 2 September 2026
여의도스토리 Ver2.0-习近平是个狗东西
@YeouidoStory2 · 58,411
Telegram ranks this channel #61 of 92 here — alongside 91 others — read 2 September 2026
신영증권 박소연
@sypark_strategy · 29,465
Telegram ranks this channel #64 of 91 here — alongside 90 others — read 8 September 2026
유진투자증권 코스닥벤처팀
@SmallCap · 23,176
Telegram ranks this channel #65 of 96 here — alongside 95 others — read 19 September 2026
주식 급등일보🚀급등테마·대장주 탐색기 | Korean Stocks
@FastStockNews · 128,921
Telegram ranks this channel #71 of 92 here — alongside 91 others — read 2 September 2026
[메리츠 Tech 김선우, 양승수, 김동관]
@merITz_tech · 24,059
Telegram ranks this channel #72 of 92 here — alongside 91 others — read 17 September 2026
이지스스트레티지 리서치
@jeilstock · 26,472
Telegram ranks this channel #84 of 93 here — alongside 92 others — read 12 September 2026

This channel appears in 10 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 18 September 2026 — this entry's latest reading, not the date you are reading this.

“허혜민의 제약/바이오 소식통” (@huhpharm), 24,282 subscribers as measured 18 September 2026. Telegram Register, tgregister.com/channel/huhpharm.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.